Yanan Zhang

Yanan Zhang

Auto-generated profile, based on publicly available information

Yanan Zhang

Department of Pediatrics, Jinshan Hospital of Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Human Gene Therapy
Verified
Journal Article
Closed access
YZYanan Zhang
Yanan Zhang
DTDingyue Tang
Dingyue Tang
WLWang Li
Wang Li
JYJing Yang
Jing Yang
XWXia Wu
Xia Wu
JWJianshe Wang
Jianshe Wang
Zinc finger FYVE-type containing 19 (ZFYVE19) deficiency, caused by biallelic ZFYVE19 complete loss-of-function variants, is a recently identified chronic hepatobiliary disorder characterized by obvious portal-tract fibrosis, increased numbers of bile ducts with malformations, and abnormal levels of serum markers of hepatobiliary injury. As liver-targeted adeno-associated virus (AAV) gene therapy has been used successfully in hepatobiliary diseases, liver-targeted gene therapy has been explored in a mouse model of this disorder. Three ZFYVE19 AAV vectors (AAV-hZFYVE19, AAV-hZFYVE19-m, and AAV-hZFYVE19-co) were constructed and injected into Zfyve19-/- mice, which were treated with alpha-naphthyl isothiocyanate (ANIT), a hepatobiliary toxin. Hematoxylin/eosin (H&E), immunohistochemical (IHC) staining, immunofluorescence (IF) staining, Sirius red staining, RT-qPCR, and western blotting (WB) of liver tissue, along with serum hepatobiliary injury markers analyses, were performed to evaluate the effects of gene therapy. AAV-hZFYVE19 decreased serum hepatobiliary injury markers, portal-tract inflammation, ductal hyperplasia, and portal-tract fibrosis in Zfyve19-/- model mice most substantially at a relatively low dose (1 × 1011 vg/kg), whereas AAV-hZFYVE19 at a higher dose gradually lost the above-mentioned benefits and even caused deterioration at the highest dose of 5 × 1012 vg/kg. These observations verified the pathogenicity of ZFYVE19 deficiency and suggested that the ZFYVE19 gene needs to function well at an optimal level of expression; both too low or too high ZFYVE19 expression may be harmful.